CERA

Science and Research

Clinical genetics research

Our team is devoted to understanding the molecular mechanisms of blinding eye diseases. We apply innovative biotechnology and bioinformatic solutions to study these diseases and develop new treatments.

Overview

Our research interests lie in understanding the molecular mechanisms of blinding eye diseases. Our group applies cutting-edge, leading biotechnology and bioinformatics solutions to better understand and treat these diseases.

This is central to our role as clinical researchers – bridging the gap between laboratory science and patient care.

Our team conducts a range of studies based on genetics, epigenetics, transcriptomics and proteomics. We work across many different diseases, and across many different technological platforms. The key factor that underpins this is direct access to well characterised patients.

Why this research is important

We are most interested in new biological technologies that are being developed, that have the potential to answer almost any question in biology.

In the near future, this will mean better treatments for devastating conditions such as glaucoma, macular degeneration and inherited retinal diseases.

Key research questions

  • Why do common and complex eye diseases develop?
  • What are the molecular underpinnings of these diseases?
  • How can emerging biotechnologies be best used to treat inherited blinding disease?